Early Phase 2a data suggest the IPF therapy GRI-0621 alters gene activity tied to inflammation, scarring, and tissue repair.

It took a while for columnist Kylene Henderson's husband, Donnie, to be diagnosed with an autoimmune disease that led to ...

The activity levels of four genes linked to the Notch pathway could help in achieving an earlier diagnosis of idiopathic ...

I’ve been writing recently about the four pillars of the Pulmonary Fibrosis Foundation’s (PFF) new five-year strategic plan introduced last year, called “The PFF Is ME.” Danoff is also a professor of ...

The European Medicines Agency has granted orphan drug status to LTI-03, an inhaled therapy being developed for people with IPF.

New Phase 2a data show the oral IPF therapy GRI-0621 modulates immune cell activity in adults with idiopathic pulmonary fibrosis.

BMS-986020 is an anti-fibrotic drug being developed by Bristol-Myers Squibb, and is chemically a lysophosphatidic acid (LPA) receptor antagonist. The drug, an oral formulation, is in clinical trials ...

There are moments in life when love challenges us to rise in unexpected ways, testing our resilience and adaptability while revealing the quiet strengths we didn’t know we had. I am currently ...

The U.S. Food and Drug Administration (FDA) has approved Jascayd (nerandomilast), taken as oral tablets, as a treatment for adults with progressive pulmonary fibrosis (PPF), in which lung scarring ...

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...